GCT-008

About Global Cancer Technology

Global Cancer Technology is a private, pre-revenue biotech targeting high-unmet-need cancers, particularly glioblastoma multiforme (GBM). Its core technology involves small molecule inhibitors, notably GCT-007, which uniquely targets both PI3K and mTOR pathways to overcome resistance and modulate the tumor microenvironment. The company is in preclinical development, with ambitious goals to initiate Phase 1/2 trials by 2027, and is currently raising capital from accredited investors.

Therapeutic Areas